Risk of Coronavirus Disease 2019-Associated Pulmonary Aspergillosis Based on Corticosteroid Duration in Intensive Care Patients.
CAPA
COVID-19
aspergillosis
corticosteroids
critically ill
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
20
10
2022
entrez:
7
3
2023
pubmed:
8
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a potential complication in critically ill COVID-19 patients. Corticosteroids are standard of care for hospitalized COVID-19 patients but carry an increased risk of secondary infections including CAPA. The objective of this study was to evaluate if duration of corticosteroid therapy ≤10 days versus >10 days affects the risk of developing CAPA. This was a retrospective cohort study of adult patients with severe COVID-19 pneumonia requiring mechanical ventilation who received at least 3 days of corticosteroid treatment. Incidence of CAPA and secondary outcomes were compared using appropriate bivariable analyses. Steroid duration was evaluated as an independent predictor in a logistic regression model. A total of 278 patients were included (n = 169 for ≤10 days' steroid duration; n = 109 for >10 days). CAPA developed in 20 of 278 (7.2%) patients. Patients treated with >10 days of corticosteroid therapy had significantly higher incidence of CAPA (11.9% vs 4.1%; Corticosteroid treatment >10 days in critically ill COVID-19 patients is associated with an increased risk of CAPA. Patients may require corticosteroids for reasons beyond COVID-19 and clinicians should be cognizant of risk of CAPA with prolonged courses.
Sections du résumé
Background
UNASSIGNED
Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a potential complication in critically ill COVID-19 patients. Corticosteroids are standard of care for hospitalized COVID-19 patients but carry an increased risk of secondary infections including CAPA. The objective of this study was to evaluate if duration of corticosteroid therapy ≤10 days versus >10 days affects the risk of developing CAPA.
Methods
UNASSIGNED
This was a retrospective cohort study of adult patients with severe COVID-19 pneumonia requiring mechanical ventilation who received at least 3 days of corticosteroid treatment. Incidence of CAPA and secondary outcomes were compared using appropriate bivariable analyses. Steroid duration was evaluated as an independent predictor in a logistic regression model.
Results
UNASSIGNED
A total of 278 patients were included (n = 169 for ≤10 days' steroid duration; n = 109 for >10 days). CAPA developed in 20 of 278 (7.2%) patients. Patients treated with >10 days of corticosteroid therapy had significantly higher incidence of CAPA (11.9% vs 4.1%;
Conclusions
UNASSIGNED
Corticosteroid treatment >10 days in critically ill COVID-19 patients is associated with an increased risk of CAPA. Patients may require corticosteroids for reasons beyond COVID-19 and clinicians should be cognizant of risk of CAPA with prolonged courses.
Identifiants
pubmed: 36879627
doi: 10.1093/ofid/ofad062
pii: ofad062
pmc: PMC9984984
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad062Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors have no conlicts of interest related to this work.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Infect Dis. 2022 Jan 7;74(1):83-91
pubmed: 33693551
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
J Hosp Infect. 2021 Jul;113:115-129
pubmed: 33891985
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Microbiol Spectr. 2021 Oct 31;9(2):e0113821
pubmed: 34668768
J Fungi (Basel). 2021 Dec 11;7(12):
pubmed: 34947049
JAMA. 2021 Nov 9;326(18):1807-1817
pubmed: 34673895
Am J Respir Crit Care Med. 2021 Feb 1;203(3):307-317
pubmed: 33480831
Crit Care. 2020 Dec 14;24(1):696
pubmed: 33317589
Crit Care. 2022 Jan 28;26(1):30
pubmed: 35090528
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
J Intensive Med. 2021 Aug 07;1(2):71-80
pubmed: 36785564
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
Front Med (Lausanne). 2021 Jan 18;7:602732
pubmed: 33537328
Front Pharmacol. 2021 May 26;12:670170
pubmed: 34122093
Mycoses. 2021 Sep;64(9):993-1001
pubmed: 33896063
Mycoses. 2021 Feb;64(2):132-143
pubmed: 33210776
Front Med (Lausanne). 2021 Nov 16;8:753659
pubmed: 34869450
Infection. 2022 Feb;50(1):43-56
pubmed: 34570355
Clin Microbiol Infect. 2020 Dec 13;:
pubmed: 33316401
Rev Bras Ter Intensiva. 2020 Jul-Sep;32(3):354-362
pubmed: 33053024
Emerg Infect Dis. 2021 Nov;27(11):2892-2898
pubmed: 34519638